- Home | Otsuka US
Otsuka is a healthcare company driven by our purpose and defined by our beliefs
- Who We Are | Otsuka US
Otsuka is a global healthcare company with two US offices and a network of 183 companies operating in 28 countries around the globe
- Products | Otsuka US
Below is a full list of the products marketed and commercialized in the US by OAPI that have been either developed, acquired, or in-licensed by Otsuka Our product specialties include neuroscience, digital innovation, nephrology, oncology, and medical devices
- Join Otsuka | Otsuka US
Looking to join the Otsuka team? Learn more about positions, openings, and locations
- News Press | Otsuka US
News Media Learn more about the latest happenings at Otsuka Select to see US news or read our press releases You can also stay up to date with our global news in the link below
- Research | Otsuka US
Otsuka’s enduring perseverance in advancing treatments for individuals living with kidney disease and immune-mediated conditions has led to breakthroughs that significantly reshape treatment landscapes and pave the way for further innovation
- Our Leadership - Otsuka US
With over 25 years of experience in clinical, academic, pharmaceutical medicine, and drug development, John upholds Otsuka’s mission to create new products for better health worldwide
- Otsuka Announces Positive Interim Results from the Phase 3 Trial of . . .
Otsuka Pharmaceutical Development Commercialization, Inc and Otsuka Pharmaceutical, Co Ltd today announce positive topline interim data from the ongoing Phase 3 clinical trial of sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgA nephropathy) in adults
|